Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Episode 92 with Dr. Shiv Saidha on using OCT to understand MS
Episode 90 with Dr. Daniel Hartung on pricing trends for MS disease-modifying therapies in the US
Single Calcitriol Dose Beats Back EAE in Mice
Microglia, Molecularly Defined
Can Gut Microbes Provide Answers About MS?
Time to Rethink CIS Criteria
159 Genetic Variants Now Known to Be Associated With MS
Brain Atrophy, Early Antibody Spread in Pediatric MS
DMT Discontinuation Review Stirs MS Research Community
The Power of Positive Thinking
Episode 96 with Drs. Bibiana Bielekova and Mika Komori on a new CSF biomarker for MS
ONO-4641
Is Cognitive MS a Distinct Entity?
Flupirtine
Naltrexone
MS Research Roundup: April 8, 2014
Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.
Ultraviolet Light Sends Soothing Cells to CNS
How should we refer to someone with MS?
Episode 93 with Dr. Lilyana Amezcua on MS in the Hispanic community
Neuromyelitis Optica, Part 2: Pathogenesis
Sustained low rate of brain volume loss under long-term fingolimod treatment in relapsing multiple sclerosis: results from the LONGTERMS study
Anti-EBV Serology, HLA-DR Risk Profiles May Help Identify MS
Episode 97 with Dr. David Baker on MS drug development and trial design
The Oligodendrocyte Whisperer
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »
